Daniel Tassé is currently Chairman and CEO of Alcresta Therapeutics, a drug-device company specializing in treating pancreatic insufficiency in many rare diseases. An accomplished healthcare executive, Mr. Tassé has built and led businesses with global footprints in the fields of bio-pharmaceuticals, medical devices, diagnostics, and health services. Prior to joining Alcresta Therapeutics, Mr. Tassé was Chairman and Chief Executive Officer of Ikaria, Inc. from 2008 until the $2.3 billion sale of the company to Mallinckrodt in April 2015, which he orchestrated. During his tenure at Ikaria, Mr. Tassé transformed the company's business model, drove significant sales and earnings growth, led the company's expansion to Asia, and successfully split Ikaria into two companies (Ikaria and Bellerophon Therapeutics) to best leverage the technical, commercial, and financial strengths of those businesses.
Prior to Ikaria, Mr. Tassé led the Pharmaceutical Technologies Business Unit of Baxter, a global business with $2 billion in revenue. Before joining Baxter, Mr. Tassé was based in Melbourne, Australia, where he was responsible for the Austral-Asian business of GlaxoSmithKline. From 2011 until 2015, Mr. Tassé was a Board Director of PhRMA, a member of the Healthcare Leadership Council, and a member of the Health Section Governing Board of BIO.
Mr. Tassé is currently a Director of Indivior PLC (London Stock Exchange: INDV), where he is a member of the Audit Committee and the Compensation Committee; of Bellerophon Therapeutics (NASDAQ: BLPH); and of Regenxbio (NASDAQ: RGNX) where he is a member of the Compensation Committee. Mr. Tassé sits on the Sheikh Zayed Institute Business Advisory Council in DC. Daniel Tassé holds a B.Sc. in Biochemistry from Universite de Montreal, and is fluent in both French and English.‹ Back to Our Team